USAQ
Price
$0.09
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
WUXIF
Price
$3.78
Change
-$0.00 (-0.00%)
Updated
Sep 10 closing price
Ad is loading...

USAQ vs WUXIF

Header iconUSAQ vs WUXIF Comparison
Open Charts USAQ vs WUXIFBanner chart's image
QHSLab
Price$0.09
Change-$0.00 (-0.00%)
Volume$1K
CapitalizationN/A
Wuxi Apptec
Price$3.78
Change-$0.00 (-0.00%)
Volume$2.22K
CapitalizationN/A
USAQ vs WUXIF Comparison Chart
Loading...
View a ticker or compare two or three
VS
USAQ vs. WUXIF commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is USAQ is a Hold and WUXIF is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (USAQ: $0.09 vs. WUXIF: $3.78)
Brand notoriety: USAQ and WUXIF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: USAQ: 7% vs. WUXIF: 102%
Market capitalization -- USAQ: $698.66K vs. WUXIF: $31.13B
USAQ [@Medical Specialties] is valued at $698.66K. WUXIF’s [@Medical Specialties] market capitalization is $31.13B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

USAQ’s FA Score shows that 0 FA rating(s) are green whileWUXIF’s FA Score has 1 green FA rating(s).

  • USAQ’s FA Score: 0 green, 5 red.
  • WUXIF’s FA Score: 1 green, 4 red.
According to our system of comparison, WUXIF is a better buy in the long-term than USAQ.

Price Growth

USAQ (@Medical Specialties) experienced а +8.24% price change this week, while WUXIF (@Medical Specialties) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.22%. For the same industry, the average monthly price growth was +0.64%, and the average quarterly price growth was +2.87%.

Industries' Descriptions

@Medical Specialties (-2.22% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

FUNDAMENTALS
Fundamentals
WUXIF($31.1B) has a higher market cap than USAQ($699K). USAQ YTD gains are higher at: 2.222 vs. WUXIF (-61.934). WUXIF has higher annual earnings (EBITDA): 11.4B vs. USAQ (-473.6K). WUXIF has more cash in the bank: 9.95B vs. USAQ (93.1K). USAQ has less debt than WUXIF: USAQ (1.63M) vs WUXIF (5.73B). WUXIF has higher revenues than USAQ: WUXIF (39.8B) vs USAQ (1.24M).
USAQWUXIFUSAQ / WUXIF
Capitalization699K31.1B0%
EBITDA-473.6K11.4B-0%
Gain YTD2.222-61.934-4%
P/E RatioN/A19.57-
Revenue1.24M39.8B0%
Total Cash93.1K9.95B0%
Total Debt1.63M5.73B0%
FUNDAMENTALS RATINGS
USAQ: Fundamental Ratings
USAQ
OUTLOOK RATING
1..100
29
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
53
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
16

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X90584.1640002628.351600
+2.99%
Bitcoin cryptocurrency
TSLA330.241.75
+0.53%
Tesla
AAPL225.120.89
+0.40%
Apple
SPY597.190.29
+0.05%
SPDR® S&P 500® ETF Trust
GME26.46-0.38
-1.42%
GameStop Corp

USAQ and

Correlation & Price change

A.I.dvisor tells us that USAQ and BIOQ have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that USAQ and BIOQ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To USAQ
1D Price
Change %
USAQ100%
N/A
BIOQ - USAQ
27%
Poorly correlated
N/A
ADMT - USAQ
21%
Poorly correlated
-17.95%
TLTFF - USAQ
9%
Poorly correlated
+2.68%
WUXIF - USAQ
7%
Poorly correlated
N/A
XVIPF - USAQ
4%
Poorly correlated
N/A
More

WUXIF and

Correlation & Price change

A.I.dvisor tells us that WUXIF and BRSYF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that WUXIF and BRSYF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WUXIF
1D Price
Change %
WUXIF100%
N/A
BRSYF - WUXIF
27%
Poorly correlated
N/A
NSTM - WUXIF
21%
Poorly correlated
-53.76%
FDMDF - WUXIF
21%
Poorly correlated
N/A
USAQ - WUXIF
7%
Poorly correlated
N/A
BDSX - WUXIF
6%
Poorly correlated
N/A
More